India cuts prices of hundreds of cancer medicines, some by over 90%
Revised rates take effect November 9, offering potential relief to patients, including Bangladeshis seeking treatment in India
Indian families battling cancer are set to experience substantial financial relief as the National Pharmaceutical Pricing Authority (NPPA) has slashed prices of 543 anti-cancer medication brands starting November 9. The revised maximum retail prices include drugs like Erlotinib for lung cancer, Fludarabine for blood cancers, Fulvestrant for hormone-sensitive breast cancer, Thiotepa for chemotherapy, Abiraterone acetate for prostate cancer, and Pegfilgrastim to prevent severe white blood cell deficiency post-treatment.
Some of the most significant reductions stand at 93.3 percent, giving families hope for diminished treatment expenses. However, the price cuts do not apply to all medications, and individual costs may vary. While financial setbacks are expected for many, the move offers substantial relief for those frequently purchasing expensive medicines.
The news has brought hope to patients like Faruk Hossain, who traveled from Dhaka to Kolkata for treatment at Apollo Hospital, believing the decision will alleviate the financial strain on his mother's treatment.
Written by urgent.news from Daily Star BD Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
